Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer – Xconomy
Xconomy |
Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer
Xconomy The FDA approval for (NYSE: MRK) pembrozlizumab (Keytruda) to treat metastatic nonsquamous non-small cell lung cancer widens the use of the immunotherapy. Last year, the FDA approved it for lung cancer patients whose tumors produce a high amount … US FDA approves Merck immunotherapy/chemo combo for lung cancer Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval Why Merck's Keytruda Just Became a Lung Cancer Game Changer |
